The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ELCC 2019 | The promise of stereotactic radiotherapy for oligometastases
In this video, Françoise Mornex, MD, PhD, of Claude Bernard University, Lyon, France, discusses the current state of radiotherapy in the treatment of oligometastatic non-small cell lung cancer (NSCLC). Prof. Mornex reports that although the improved survival outcomes demonstrated by patients treated with stereotactic irradiation is extremely promising, further research is required to determine the optimal dosage and timing of the radiation delivered to NSCLC patients. This interview took place at the European Lung Cancer Congress (ELCC) 2019, held in Geneva, Switzerland.
